Uğur Şahin, BioNTech CEO (Sebastian Gollnow/picture-alliance/dpa/AP Images)
November 6, 2023 07:40 AM EST
Deals
China

BioN­Tech grabs PD-L1/VEGF bis­pe­cif­ic with $55M up­front, ex­pand­ing pipeline while low­er­ing Covid guid­ance

Amber Tong

Kyle LaHucik

Senior Reporter

As BioN­Tech con­tin­ues to beef up its on­col­o­gy pipeline, it’s once again turn­ing to a Chi­nese part­ner.

The Ger­man biotech is putting down $55 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times